Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive
SUBMITTER: Elisabetta Marangoni Emily Pepper
PROVIDER: MTBLS3342 | MetaboLights | 2023-06-27
REPOSITORIES: MetaboLights
Items per page: 1 - 5 of 15 |
Nature communications 20230714 1
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell lines we demonstrate that a fraction of metastatic ER + BC is highly reliant on oxidative phosphorylation (OXPHOS). Treatment by the OXPHOS inhibitor IACS-010759 strongly inhibits tumour growth in multipl ...[more]